RT Journal Article
SR Electronic
T1 Plasma cytokine levels reveal deficiencies in IL-8 and gamma interferon in Long-COVID
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.10.03.22280661
DO 10.1101/2022.10.03.22280661
A1 Elizabeth S. C. P. Williams
A1 Thomas B. Martins
A1 Harry R. Hill
A1 Mayte Coiras
A1 Kevin S. Shah
A1 Vicente Planelles
A1 Adam M. Spivak
YR 2022
UL http://medrxiv.org/content/early/2022/10/05/2022.10.03.22280661.abstract
AB Up to half of individuals who contract SARS-CoV-2 develop symptoms of long-COVID approximately three months after initial infection. These symptoms are highly variable, and the mechanisms inducing them are yet to be understood. We compared plasma cytokine levels from individuals with long-COVID to healthy individuals and found that those with long-COVID had 100% reductions in circulating levels of interferon gamma (IFNγ) and interleukin-8 (IL-8). Additionally, we found significant reductions in levels of IL-6, IL-2, IL-17, IL-13, and IL-4 in individuals with long-COVID. We propose immune exhaustion as the driver of long-COVID, with the complete absence of IFNγ and IL-8 preventing the lungs and other organs from healing after acute infection, and reducing the ability to fight off subsequent infections, both contributing to the myriad of symptoms suffered by those with long-COVID.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the University of Utah Inflammation Immunology and Infectious Diseases Initiatives Emerging Infectious Diseases Fellowship (recipient ESCPW) and by a seed grant from the University of Utah Vice President for Research and the Immunology Inflammation and Infectious Disease Initiative (recipient VP). VP and MC were supported by NIH GRANT 5R01-AI143567.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of the University of Utah gave ethical approval for this work under IRB_00131664 on 11/20/2020.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.